Ebola vaccine research is moving ahead at lightening speed thanks to combined public and private sector efforts, with GlaxoSmithKline unveiling fresh data showing that its experimental jab protected monkeys in a preclinical study.
GlaxoSmithKline may have a bigger problem in China than previously thought. Before news about potential corruption in its pharma business surfaced, U.S. officials were already looking into possible bribery in its consumer healthcare unit. And so was GSK.
A vaccine under development by GlaxoSmithKline to prevent Ebola infection showed protection in monkeys that were exposed to the deadly pathogen. But if given to people, the preventive method would likely require a booster shot after the initial inoculation, according to a new study.
GlaxoSmithKline is looking to set some drug development records as it races to the clinic with an Ebola vaccine, posting promising results in preclinical study as a public health crisis unfolds in Africa.
Investigators for GlaxoSmithKline detailed their promising Phase III data for the IL-5 biologic mepolizumab in asthma today, noting that the injectable halved the rate of exacerbations among a group of patients with uncontrolled cases of the respiratory disease. But while the pharma giant was making its case for a lower dosage of the drug for a particular profile of asthma patient, an expert in the field raised the prospect that GSK's biggest competitor in the real world may simply be cheaper therapies applied with proper compliance to the medical guidelines already in place.
GlaxoSmithKline's Canadian flu vaccine plant has been in the spotlight recently for problems that spurred an FDA warning letter and a talking-to from Health Canada. But it's different problems that the British drugmaker now says will keep it from filling about 30% of its Canadian order for this season--and they could compromise some of its U.S. shipments, too.
Hot on the heels of its FDA approval, a new combo pill from the HIV-focused partnership of GlaxoSmithKline and Pfizer, has won approval in Europe. ViiV Healthcare said that the EU had given a green light to its once daily combo pill Triumeq, an approval that will help it reach the $5 billion in peak sales it has been forecast to capture.
GlaxoSmithKline's image has taken a beating this past year, what with a string of bribery investigations unfolding across China, Europe and the Middle East. And as part of the company's efforts to put a fresh face forward, its websites are getting a makeover.
GSK vet Jason Gardner is the newly named VP for R&D in the greater Boston area, in charge of a small but growing team of specialists at a brand-new satellite facility that will help coordinate not only the 25-or-so ongoing scientific collaborations with groups like the Harvard Stem Cell Institute but also biotech partnerships with the likes of Epizyme.
Glaxo, say hello to another Advair rival in Germany and Sweden. Monday, Indian generics maker Cipla rolled out its copy of GSK's respiratory behemoth in the two European countries, and the company's CEO says more are on the way.